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Introduction
The proline/arginine-rich end leucine-rich repeat (LRR) protein 
(PRELP) is a 58-kD heparin/heparan sulfate–binding protein 
first discovered in articular cartilage but present also in several 
connective tissue extracellular matrices. The protein comprises 
382 aa residues, including a 20-residue signal peptide. It be-
longs to a subfamily of LRR proteins in the extracellular matrix. 
Members encompass several small LRR proteins (SLRRPs), in-
cluding the chondroitin/dermatan sulfate proteoglycans decorin 
and biglycan and the keratan sulfate proteoglycans fibromodulin 
and lumican (Iozzo and Murdoch, 1996). 10–11 adjacent LRRs 
characterize this subfamily, flanked at either end by disulphide-
bonded domains (Heinegård et al., 2002).
N-linked oligosaccharides are present in the central LRR 
domain of PRELP (Bengtsson et al., 1995), whose name reflects 
the abundance of proline and arginine in its N-terminal domain 
(Bengtsson et al., 1995). Compared with many of the other 
members of the SLRRP subfamily, PRELP has two atypical 
features. First, it does not contain glycosaminoglycan (GAG) 
chains; second, the N-terminal region, which is unique and con-
served between rodents, bovine, and humans, binds heparin and 
heparan sulfate (Bengtsson et al., 2000). N-terminally truncated 
PRELP lacking this region cannot bind heparin, whereas a 6-mer 
heparin oligosaccharide is the smallest size showing some affin-
ity to PRELP. Binding increases with length up to 18-mer and 
was found to depend on the degree of sulfation of heparin and 
heparan sulfate (Bengtsson et al., 2000). The protein binds 
collagens I and II with high affinity (Bengtsson et al., 2002) via 
its LRR domain, whereas the N-terminal part of PRELP can 
bind the heparan sulfate of perlecan or bind fibroblasts via 
surface heparan sulfate proteoglycans (Bengtsson, 1999), thus 
  P
roline/arginine-rich end leucine-rich repeat protein 
(PRELP) is a glycosaminoglycan (GAG)- and collagen-
binding anchor protein highly expressed in car-
tilage, basement membranes, and developing bone. We 
observed that PRELP inhibited in vitro and in vivo mouse 
osteoclastogenesis  through  its  GAG-binding  domain 
(
hbdPRELP), involving (a) cell internalization through a chon-
droitin sulfate– and annexin II–dependent mechanism, 
(b) nuclear translocation, (c) interaction with p65 nuclear 
factor B (NF-B) and inhibition of its DNA binding, 
and (d) impairment of NF-B transcriptional activity and 
reduction of osteoclast-specific gene expression. 
hbdPRELP 
does not disrupt the mitogen-activated protein kinase sig-
naling nor does it impair cell survival. 
hbdPRELP activity is 
cell  type  specific,  given  that  it  is  internalized  by  the 
RAW264.7  osteoclast-like  cell  line  but  fails  to  affect   
calvarial osteoblasts, bone marrow macrophages, and 
epithelial cell lines. In vivo, 
hbdPRELP reduces osteoclast 
number and activity in ovariectomized mice, underlying 
its physiological and/or pathological importance in skel-
etal remodeling.
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with vehicle, 
hbdPRELP, or the control peptide and with the 
bisphosphonate alendronate as a reference drug. 
hbdPRELP sig-
nificantly reduced the ovariectomy-induced increase of the urine 
bone resorption marker C-terminal collagen I cross-links (CTX; 
Fig. 2 A). In histological sections of proximal tibia, secondary 
spongiosa osteoclast number as well as osteoclast surface per 
bone surface area were decreased in ovariectomized mice treated 
with 
hbdPRELP versus vehicle- and control peptide–treated mice 
(Fig. 2, B–D). Consistently, the analysis of trabecular bone struc-
tural parameters (Fig. 2, E–H) showed the ability of 
hbdPRELP 
to significantly reduce the ovariectomy-induced bone loss.
Mechanism of action
We next sought to establish when the peptide was active during 
in vitro osteoclast formation. Fig. 3 A shows that 
hbdPRELP re-
duced osteoclastogenesis both when given for the entire period 
of culture and during the last 3 d, whereas it was inactive when 
administered only throughout the first 3 d. The effect was irre-
versible in that treatment with 15 µM 
hbdPRELP for 5 d followed 
by 
hbdPRELP withdrawal, and continuation of the culture for a 
further 5 d did not result in the induction of osteoclastogenesis 
(unpublished data). Moreover, 
hbdPRELP significantly reduced 
adhesion  when  cells  were  pretreated  in  suspension  with  the   
peptide before seeding them in the culture dish (Fig. 3 B). This 
result suggests interference with cell surface molecules, per-
haps proteoglycans.
Role of cell surface proteoglycans
To address whether cell surface proteoglycans carrying heparan 
sulfate chains were involved in the inhibitory effect by 
hbdPRELP 
on osteoclast formation, we performed osteoclastogenesis as-
says in the presence of heparinase III. Surprisingly, this treat-
ment was unable to rescue osteoclast formation in the presence 
of 
hbdPRELP (Fig. 3 C). Therefore, we next investigated the in-
volvement of cell surface proteoglycans substituted with chon-
droitin sulfate chains (Deepa et al., 2004). Indeed, we observed 
that pretreatment of prefusion osteoclast cultures with chon-
droitinase ABC prevented 
hbdPRELP from inhibiting osteoclast 
formation (Fig. 3 D). Confocal microscopy with a specific anti-
body confirmed that chondroitin sulfate was expressed by pre-
fusion osteoclasts and was removed from the cell surface after 
treatment with chondroitinase (Fig. 3 E). Moreover, chondroitin 
sulfate largely colocalized with a 
hbdPRELP peptide tagged with 
biotin (Biotin
hbdPRELP; Fig. 3 F).
Internalization of 
hbdPRELP
The 
hbdPRELP  sequence  contains  eight  arginine  residues  in   
motifs typical of viral proteins prone to be internalized by eukary-
otic cells (Futaki et al., 2001). Therefore, we hypothesized that 
hbdPRELP may be internalized and affect osteoclastogenesis via 
an intracellular target. To address this aspect, we vitally incu-
bated prefusion osteoclasts with Biotin
hbdPRELP and monitored 
its uptake by confocal microscopy. After 5 min, Biotin
hbdPRELP 
was mostly localized at the cell surface in structures reminis-
cent of membrane rafts (Fig. 4 A, a), whereas after 10 min, it 
was internalized in endosomal vesicles (Fig. 4 A, b). Interest-
ingly, after 20 min, Biotin
hbdPRELP was mainly found in the 
serving as a linker between these proteoglycans and the extra-
cellular matrix.
The gene encoding PRELP maps at chromosome 1q32, 
and PRELP mRNA transcripts were found in articular chondro-
cytes, osteoblasts, and osteosarcoma cells of various species 
(Bengtsson et al., 2000). The protein was also found at base-
ment membranes of skin, testis, and Bowman’s capsule of the 
kidney (Bengtsson et al., 2002). PRELP plays a role in eye and 
skin (Reardon et al., 2000; Grover et al., 2007). The protein is 
highly expressed in human sclera, and mutations have been 
found in advanced myopia (Majava et al., 2007). PRELP muta-
tions are also involved in the pathogenesis of Hutchinson-Gilford 
progeria (Lewis, 2003), which is characterized, among other 
symptoms, by scleroderma, achondrogenesis, bone deformities, 
and osteoporosis (Hennekam, 2006).
Although PRELP was found in the skeleton expressed by 
chondrocytes and osteoblasts, there is no direct information re-
garding the role of the protein in skeletal remodeling. We sought 
to identify its role in bone homeostasis using an N-terminal pep-
tide corresponding to the entire heparin-binding domain of PRELP 
(
hbdPRELP). The peptide was tested in in vitro cultures of mouse 
osteoblasts and osteoclasts and in a mouse model of bone loss. Al-
though 
hbdPRELP had no effect on osteoblasts and other cell types, 
it impaired osteoclastogenesis and bone resorption by a mecha-
nism requiring its internalization, translocation to the nucleus, and 
inhibition of the transcription factor nuclear factor B (NF-B).
Results
Effect of 
hbdPRELP on osteoclastogenesis 
and bone resorption
In vitro osteoclastogenesis assays showed that 
hbdPRELP but not 
our control heparin-binding peptide remarkably reduced osteo-
clast formation from unfractionated bone marrow cells treated 
with 1,25(OH)2VitaminD3 (Fig. 1 A). The 
hbdPRELP effect was 
concentration dependent, with a calculated IC50 of 7.3 µM and a 
narrow range of optimal concentrations (Fig. 1 B). Consistent 
with the impairment of osteoclast generation, 
hbdPRELP signifi-
cantly reduced pit number (Fig. 1 C). Furthermore, 
hbdPRELP 
appeared to have a direct effect on the osteoclast lineage,   
as demonstrated by the inhibition of osteoclastogenesis in puri-
fied bone marrow macrophage cultures treated with macrophage   
colony-stimulating factor (M-CSF) and receptor activator of   
NF-B (RANK) ligand (RANKL; Fig. 1 D). Notably, this effect 
was observed also using the intact PRELP protein, which showed 
a potency similar to that of the 
hbdPRELP peptide (Fig. 1 E). Fi-
nally, in osteoclasts previously differentiated by treatment with 
M-CSF and RANKL and then transferred onto bone slices and 
subsequently treated with 
hbdPRELP for 48 h, the peptide failed to 
affect pit formation, suggesting that the major effect is exerted on 
the mechanism of osteoclast formation rather than on that of bone 
resorption (Fig. S1 A).
Effect of 
hbdPRELP in vivo
To assess whether 
hbdPRELP may also have a role in vivo, we 
increased osteoclast activity and induced bone loss in female 
mice by ovariectomy (Idris et al., 2008) and treated the animals 671 PRELP and osteoclastogenesis • Rucci et al.
Figure 1.  Effect of 
hbdPRELP on osteoclastogenesis and bone resorption. (A and B) Unfractionated mouse bone marrow cells were incubated in the presence   
of 1,25(OH)2VitaminD3 with vehicle, 15 µM 
hbdPRELP, or 15 µM of control peptide (A) or with the indicated concentrations of 
hbdPRELP (B). Osteoclasts   
were then stained for TRAcP, enumerated, and expressed as the percentage of vehicle treated. (C) Pit index of cells cultured as in A but onto bone slices.   
(D) Bone marrow macrophages were incubated for 6 d with 50 ng/ml M-CSF and 120 ng/ml RANKL plus vehicle or 15 µM 
hbdPRELP. Osteoclasts were   
then assessed by TRAcP staining (top) and enumerated (bottom). (E) Bone marrow macrophages were treated with 15 µM of control peptide, 15 µM 
hbdPRELP, or 15 µM of intact PRELP, and osteoclastogenesis was assessed as described in A. (A–E) Results are the mean ± SEM of three independent   
experiments (*, P < 0.01).JCB • VOLUME 187 • NUMBER 5 • 2009   672
Figure 2.  Effect of 
hbdPRELP in vivo. Ovariectomized (OVX) mice were treated with vehicle, 10 mg/kg body weight of 
hbdPRELP, or control peptide and   
1 mg/kg body weight of alendronate as reference drug 5 d/wk for 5 wk. (A) Quantification of the bone resorption marker CTX in urine samples. (B) Tibial 
sections stained for TRAcP activity (purple stain) to evidence osteoclasts. (C–H) Measurement of osteoclast number/bone surface (OcN/BS; C), osteoclast 
surface/bone surface (OcS/BS; D), bone volume/tissue volume (BV/TV; E), trabecular number (Tb N; F), trabecular thickness (Tb Th; G), and trabecular 
separation (Tb Sp; H). (A and C–H) Data are the mean ± SD of five mice per group (*, P < 0.05 vs. sham; 
#, P < 0.05 vs. control peptide and vehicle; 
and 
+, P < 0.05 vs. control peptide).673 PRELP and osteoclastogenesis • Rucci et al.
Figure 3.  Role of cell surface proteoglycans in 
hbdPRELP-induced inhibition of osteoclastogenesis. (A) Purified mouse bone marrow macrophages, incubated 
with M-CSF and RANKL, were treated with vehicle (0) or 15 µM 
hbdPRELP for the entire time frame of the cultures (1–6 d), for the first 3 d (1–3), or for the 
last 3 d (4–6). (B) Osteoclast cultures, differentiated by M-CSF and RANKL, were trypsinized. Cells were then pretreated in suspension with vehicle, 15 µM   
hbdPRELP, or 15 µM of control peptide and allowed to adhere to substrate for the times indicated. Attached cells were stained for TRAcP (top) and enumer-
ated (bottom). (C and D) Prefusion osteoclasts were pretreated with 2 U/ml heparinase III (C) or 0.45 U/ml chondroitinase ABC (D) before the addition   
of 
hbdPRELP, and then multinucleated osteoclasts were stained for TRAcP and enumerated. (E) Prefusion osteoclasts were pretreated with vehicle or with   
0.45 U/ml chondroitinase ABC, fixed, and incubated with an anti–chondroitin sulfate antibody (green), with no permeabilization to assess the content of 
cell surface chondroitin sulfate. Cells were also stained with DAPI (blue) to detect nuclei. Pictures are the results of the merge between the two fluorescences. 
(F) Prefusion osteoclasts were treated with a biotin-tagged 
hbdPRELP (B
hbdPRELP), fixed, permeabilized, and incubated with an anti–chondroitin sulfate anti-
body to detect colocalization of tagged 
hbdPRELP with cell surface and vesicular chondroitin sulfate (biotin 594-streptavidin [streptav] was used as a negative 
control). (A–D) Results are representative or the mean ± SEM of three independent experiments (*, P < 0.001).JCB • VOLUME 187 • NUMBER 5 • 2009   674
nucleus, and several endosomal vesicles appeared in the pro-
cess of Biotin
hbdPRELP transfer to the nuclear compartment 
(Fig. 4 A, c). Mature multinucleated osteoclasts were also able 
to internalize Biotin
hbdPRELP and retained it in the nuclei after 
20 min of vital incubation (Fig. 4 A, d). Control cultures incu-
bated with biotin-594 streptavidin alone were negative (Fig. 4 A, e). 
Similar internalization was observed with another tagged pep-
tide, Alexa Fluor 488–
hbdPRELP (Fig. S1 B).
Biotin
hbdPRELP  internalization  required  active  cellular 
processes given that the events observed at 37°C (Fig. 4 A, f) 
were inhibited when the cells were incubated at 4°C (Fig. 4 A, g). 
Furthermore, pretreatment with chondroitinase ABC abol-
ished Biotin
hbdPRELP membrane binding and internalization 
(Fig. 4 A, h). Finally, we fixed and permeabilized prefusion 
  osteoclasts and incubated these cells with Alexa Fluor 488– 
hbdPRELP.  Indeed,  we  observed  that  fluorescent 
hbdPRELP 
not only decorated membrane and intracellular compartments 
but was also largely localized in the nuclei (Fig. 4 A, i).
Interaction with cellular proteins
To address which candidate protein could interact with Biotin
hbd 
PRELP, we performed SDS-PAGE and blot transfer of untreated 
prefusion osteoclast total cell lysates, incubated the blots with 
Biotin
hbdPRELP, and visualized the biotin by HRP-conjugated 
streptavidin and ECL. Indeed, several specific bands were re-
vealed, among which, those most evident had apparent molecu-
lar masses of 35 and 65 kD (Fig. 4 B).
One important 35-kD protein known to have a central role 
in endocytosis is annexin II (Gerke et al., 2005). Indeed, by 
stripping the membrane and reprobing it with an annexin II 
  antibody, we identified this protein at 35 kD (Fig. 4, compare B 
[right] with C [left]). CD44 represents another cell surface pro-
tein known to have roles in endocytosis in many cell types 
(Aguiar et al., 1999; Jiang et al., 2002) and in the fusion process 
of osteoclast precursors (Kania et al., 1997; Sterling et al., 1998; 
Suzuki et al., 2002). However, reprobing the membrane with an 
antibody recognizing CD44 revealed a band at 80 kD (Fig. 4 C, 
middle), which did not correspond to any of the specific Biotin-
hbdPRELP bands observed in Fig. 4 B.
NF-B is a transcription factor crucial to osteoclast devel-
opment and function. One of the components labeled by Biotin-
hbdPRELP in Fig. 4 B migrated at 65 kD, which corresponds to 
the molecular mass of the p65NF-B subunit. Stripping and 
reprobing the membrane with a p65NF-B subunit antibody in-
deed confirmed the presence of this subunit at 65 kD (Fig. 4, 
compare B [right] with C [right]). To assess specific protein–
protein interactions of Biotin
hbdPRELP with our candidate pro-
teins, we performed immunoprecipitation assays in prefusion 
osteoclasts treated with vehicle or with Biotin
hbdPRELP, dem-
onstrating that indeed the tagged peptide coimmunoprecipitated 
in a complex with annexin II (Fig. 4 E) as well as in a complex 
with p65NF-B (Fig. 4 F).
Role of annexin II
We next asked what the role could be of annexin II in 
hbdPRELP 
activity. Fig. 5 A (a) shows that Biotin
hbdPRELP colocalized with 
annexin II at the cell surface and at endosomes. Interestingly, 
annexin  II  also  fully  colocalized  with  chondroitin  sulfate 
(Fig. 5 A, b). Indeed, incubation with an anti–annexin II antibody 
reduced intracellular levels of Biotin
hbdPRELP in prefusion   
osteoclasts vitally treated with the peptide (Fig. 5 B). Consistent 
with the lack of binding to CD44 (Fig. 4 C), an anti-CD44 anti-
body failed to affect the ability of prefusion osteoclasts to inter-
nalize Biotin
hbdPRELP (Fig. 5 B).
Role of the NF-B transcription factor
The transcription factor NF-B is a crucial determinant of osteo-
clastogenesis. In prefusion osteoclasts, obtained by incubation 
of bone marrow macrophages with M-CSF and RANKL for 4 d, 
p65NF-B was translocated to the nucleus (Fig. 5 C, top), and, 
in contrast to RANKL withdrawal (Fig. 5 C, middle), treatment 
with 
hbdPRELP did not displace p65NF-B from this localiza-
tion (Fig. 5 C, bottom). This suggests that 
hbdPRELP does not 
affect p65NF-B trafficking but may rather affect its transcrip-
tional activity. To test this hypothesis, we evaluated p65NF-B 
binding to DNA using a colorimetric assay (TransAM NF-B 
p65 kit), which revealed that this binding was reduced by 50% 
in 
hbdPRELP-treated prefusion osteoclasts compared with con-
trol (Fig. 5 D). Accordingly, luciferase activity assay performed 
in the immortalized osteoclast precursors cell line RAW264.7, 
which also internalized Biotin
hbdPRELP (see Fig. 8), evidenced 
a significant reduction of specific p65NF-B transcriptional ac-
tivity after treatment with 
hbdPRELP (Fig. 5 E).
Expression of osteoclast genes and activity 
of signal molecules
To confirm that NF-B activity was impaired by the treatment 
with 
hbdPRELP, we evaluated the transcriptional expression of 
downstream osteoclast-specific genes. Real time RT-PCR showed 
down-regulation of cathepsin K, CTR (calcitonin receptor), 
MMP-9 (metalloproteinase-9), rank, and TRAcP (tartrate-
resistant acid phosphatase) mRNAs (Fig. 6 A). Likewise,   
hbdPRELP reduced the expression of genes implicated in cell 
fusion such as DC-STAMP and CD44, with a modest effect also 
on MFR (macrophage fusion receptor; Fig. 6 A).
We next evaluated the effect of 
hbdPRELP on MAPK signal-
ing. Fig. 6 B shows that this treatment did not prevent RANKL-
induced phosphorylation of the MAPKs ERK1/2, JNK, and p38, 
suggesting no effect of 
hbdPRELP on immediate cell signaling 
pathways triggered by RANK activation. 
hbdPRELP also failed to 
affect cell survival. In particular, the nuclei of 
hbdPRELP-treated 
prefusion  osteoclasts,  stained  with  DAPI,  showed  no  nuclear 
fragmentation or altered morphology, indicating that apoptosis 
was not induced by treatment with 
hbdPRELP (Fig. 6 C). Consis-
tently, Western blot analysis showed no changes in protein ex-
pression of the prosurvival factor Bcl-2 and of the proapoptotic 
factor Bax nor activation of procaspase 3 (Fig. 6 D).
Specificity
To assess species cross-reactivity, we evaluated the effect of 
hbdPRELP on mouse, rat, and human osteoclastogenesis. As shown 
in Fig. S2, prefusion osteoclasts of all three species showed 
similar nuclear internalization of Alexa Fluor 488–
hbdPRELP 
(left) and inhibition of osteoclast formation (right). Fig. 7 (A–D) 675 PRELP and osteoclastogenesis • Rucci et al.
Figure 4.  Internalization of 
hbdPRELP and interacting proteins. (A) Vital incubation of prefusion (a–c) or mature mouse osteoclasts (OC; d) with Biotin 
hbdPRELP for the minutes indicated. Arrows indicate plasma membrane localization (a), localization in endosomal vesicles (b), and localization in vesicles in 
the vicinity of the nucleus (c). N, nuclei. (e) Negative control in the absence Biotin
hbdPRELP. (f–h) Prefusion osteoclasts were incubated with Biotin
hbdPRELP for 
20 min at 37°C (f) or at 4°C (g) or were pretreated with 0.45 U/ml chondroitinase ABC (h) before the incubation with Biotin
hbdPRELP. (f and g) Insets show 
higher magnification of the framed fields. (i) Fixed and permeabilized prefusion osteoclasts were incubated with Alexa Fluor 488–
hbdPRELP. The solid lines 
indicate the cell surface, and the dashed lines indicate the nuclear envelope. (B) A prefusion osteoclast lysate was subjected to SDS-PAGE and processed 
with Biotin
hbdPRELP (B
hbdPRELP) as described in Materials and methods. Asterisks indicate nonspecific bands. (C) The filter shown in B was stripped and 
Western blotted for annexin II, CD44, and p65NF-B. (D–F) Immunoprecipitation (IP) of Biotin
hbdPRELP-treated prefusion osteoclast lysates with preimmune 
serum (D), an annexin II antibody (E), or a p65NF-B antibody (F). Results are representative of three independent experiments. PIs, preimmune serum; 
TCL, total cell lysate; WB, Western blot.JCB • VOLUME 187 • NUMBER 5 • 2009   676
Figure 5.  Role of annexin II and NF-B. (A, a) Prefusion osteoclast incubation with Biotin
hbdPRELP (B
hbdPRELP; 10 min) and immunofluorescence detection 
of annexin II. (b) Immunofluorescence detection of chondroitin sulfate and annexin II. (B) Vital incubation of prefusion osteoclasts with Biotin
hbdPRELP in 
the presence of anti-CD44, anti–annexin II antibody, and an irrelevant IgG. Biotin-594 streptavidin (streptav) served as a negative control in the absence   
of Biotin
hbdPRELP. (C) Prefusion osteoclasts, treated as indicated, were incubated with an anti–p65NF-B antibody followed by incubation with   677 PRELP and osteoclastogenesis • Rucci et al.
Young et al., 2005; Majumdar et al., 2008). Interestingly, the 
heparin-binding domain representing our 
hbdPRELP has no sites 
of cleavage by these enzymes, thus suggesting that the intact 
protein could be enzymatically processed and release active 
peptides encompassing the 
hbdPRELP sequence, which can then 
act as physiological regulators of bone resorption. Of course, 
we cannot rule out that the intact protein can be internalized as 
such, a circumstance addressable only in a systematic study as 
the simple use of a tagged intact PRELP cannot distinguish be-
tween the internalization of the entire sequence versus that of 
cleaved peptides.
The level of specificity for the effect of the 
hbdPRELP is in-
teresting. A different peptide, representing the heparin-binding 
domain of chondroadherin, unexpectedly turned out to be in-
effective on osteoclast development, albeit it bound to heparin 
and was eluted at higher salt concentrations (0.8 M NaCl) com-
pared with the PRELP peptide (0.6 M NaCl; unpublished data). 
Thus, the chondroadherin peptide was chosen as an appropriate 
control for the specificity of the 
hbdPRELP peptide for a distinct 
class of cell surface GAG chains. This control peptide did not 
bind to the osteoclast precursor cells and did not affect osteoclasto-
genesis. Therefore, it is likely that the effect of the PRELP pep-
tide is restricted to a limited number of cells with a specific cell 
surface ligand GAG. The exact specificity of the PRELP peptide 
for a distinct pattern of sulfation along the chondroitin sulfate 
chain is not known. In view of previous results showing tightest 
binding to optimally sulfated heparin (Bengtsson et al., 2000), it 
is likely that the interaction involves oversulfated disaccharides. 
Because the variability of the chondroitin sulfate chain is not 
known, the definition of binding parameters and the identification 
of the specific chondroitin sulfate chain involved are important 
tasks for future work.
PRELP is expressed by osteoblasts; however, consistent 
with its high specificity, at least the 
hbdPRELP peptide used in this 
study does not appear to have any autocrine effect on these cells. 
Similarly, bone marrow macrophages and epithelial cell lines 
were insensitive to 
hbdPRELP treatment. In contrast, the peptide 
directly affected osteoclast precursors at a late stage of differenti-
ation. At this stage, a heparan sulfate proteoglycan, perlecan, not 
directly associated with the cell surface and with known ability to 
bind 
hbdPRELP was scanty or absent albeit expressed at earlier 
stages (unpublished data). In a previous study, heparan sulfate 
proteoglycans were found in mature osteoclasts (Nakano et al., 
2004), but the lack of effect of heparinase III digestion in the 
osteoclastogenesis assays rules out a role of this GAG in the 
hbdPRELP peptide activities on osteoclast development.
However,  we  believe  that  our  study  has  identified  the 
mechanisms whereby 
hbdPRELP impairs osteoclast generation. 
We found that the peptide recognizes chondroitin sulfate chains 
of cell surface proteoglycans. In a separate series of experi-
ments, we have used an Akubio RAPid-4 acoustic biosensor to 
show that chondroitin 6-sulfate (from human nucleus pulposus) 
shows that 
hbdPRELP does not affect osteoblast activity. Alexa 
Fluor  488–
hbdPRELP  did  not  vitally  bind  to  calvarial  osteo-
blasts, nor did 
hbdPRELP affect alkaline phosphatase (ALP) ac-
tivity, ability to mineralize, production of bone matrix proteins, 
and signaling protein phosphorylation. Moreover, the expres-
sion of genes representing different osteoblast functions was also 
unchanged (Table S1). Consistently, in vivo 
hbdPRELP failed to 
affect the osteoblast parameters in the tibial secondary spongi-
osa of ovariectomized mice (Fig. 7, E–G).
To assess 
hbdPRELP specificity on other cell types, we per-
formed vital incubation of mouse bone marrow macrophages 
with Alexa Fluor 488–
hbdPRELP, which was able to bind the cell 
surface at 5 min. However, this binding was not followed by pep-
tide internalization and nuclear transfer at later times (Fig. 8 A). 
In contrast, we observed 
hbdPRELP internalization in RAW264.7 
cells, representing mouse osteoclast precursors (Fig. 8 B). Vital 
incubation with tagged 
hbdPRELP of the immortalized cell lines 
HEK293 (human epithelial kidney) and MDA-MB231 (human 
breast cancer) also demonstrated no peptide internalization 
(Fig. 8 B). In addition, the MDA-MB231 cells treated with 
hbdPRELP showed no changes in proliferation, migration, and in-
vasion ability compared with vehicle-treated cells (Fig. S3), and 
HEK293 cells subjected to luciferase assay showed no sensitiv-
ity of NF-B transcriptional activity to 
hbdPRELP treatment (not 
depicted). These results suggest that 
hbdPRELP activity is spe-
cific only for certain cells such as osteoclasts of various species 
at particular stages of development.
Discussion
We believe that we have identified a novel mechanism control-
ling bone homeostasis, in which a domain of an extracellular 
matrix molecule modulates bone breakdown. The studied basic 
heparin- and, as identified in this study, chondroitin sulfate–binding 
N-terminal domain of PRELP was found to block osteoclast 
formation by a direct mechanism affecting prefusion osteoclasts 
through inhibition of p65NF-B transcriptional activity. To the 
best of our knowledge, the activity of this matrix peptide appears 
novel, involving chondroitin sulfate chains at the cell surface, 
and may represent an important new determinant to control bone 
remodeling and homeostasis. Notably, the intact PRELP had 
similar effect on osteoclast formation as the 
hbdPRELP peptide, 
and the peptide showed antiresorptive activity in vivo. These ob-
servations have two important implications: (1) the protein is 
likely to play a physiological role in the control of bone remod-
eling, and (2) the peptide has the potential to represent a new   
antiresorptive biological agent valuable for therapy.
Intact PRELP was similarly active in impairing osteo-
clastogenesis as the 
hbdPRELP. We found that a cluster of en-
zymes, which cut proteoglycans of the cartilage and/or bone 
matrices, can potentially cleave the intact PRELP (Fig. S4; 
Breckon et al., 1999; Li et al., 2004; Nakamura et al., 2004; 
FITC-conjugated secondary antibody (NF-B; left) and with propidium iodide (PI; middle) to detect nuclei. (D) Colorimetric p65NF-B DNA binding assay 
of prefusion osteoclast lysates treated with vehicle or 15 µM 
hbdPRELP. (E) RAW264.7 cells were treated with control peptide or 
hbdPRELP and subjected to 
the luciferase assay as described in Materials and methods. (D and E) Results are the mean ± SEM of three independent experiments (*, P < 0.05).
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indeed binds the Biotin
hbdPRELP peptide (unpublished data).   
Internalization and nuclear localization of Biotin
hbdPRELP has now 
been demonstrated in osteoclasts and depends on chondroitin sul-
fate because these processes are inhibited by the removal of these 
chains. Chondroitin sulfate proteoglycans have not been intensely 
investigated in osteoclasts (Li et al., 2002), and to the best of our 
knowledge, this is the first indication that they are involved in 
peptide internalization and endosome formation.
hbdPRELP is a highly cationic peptide with eight arginines 
distributed between aa 4 and 21, and this number of arginines was 
observed to be optimal for peptide internalization (Nakase et al., 
2008). In fact, highly cationic peptides are able to enter into the 
cytoplasmic compartment and nucleus of cells from the extra-
cellular environment (Futaki et al., 2002; Kosuge et al., 2008; 
El-Sayed et al., 2009), although they have no nuclear localization 
sequence. A recent study analyzing live cells demonstrated that 
these peptides enter through endocytosis and accumulate in 
endocytic vesicles without necessarily routing via the cytoplasm 
(Futaki et al., 2007). Arginine-rich peptides, including a basic 
peptide segment derived from the HIV-1 Tat protein, are catego-
rized into one of the most frequently used peptide vectors (Futaki 
et al., 2007), and their uptake is dependent on heparan sulfate and 
chondroitin sulfate proteoglycans (Nakase et al., 2007). This is in 
line with our study and corroborates our observations that cell 
surface chondroitin sulfate chains are indispensable for the mech-
anism of action of 
hbdPRELP in osteoclasts.
In contrast, Biotin
hbdPRELP internalization was totally inde-
pendent of CD44 activity. This type I transmembrane glyco-
protein is expressed by the osteoclast lineage, is involved in fusion 
of macrophages, and binds several matrix components, including 
hyaluronan, and its occupancy by matrix components prevents the 
formation of polykaria (Sterling et al., 1998). However, CD44 
mRNA expression is impaired by 
hbdPRELP treatment, thus con-
tributing to its inhibitory effect through a transcriptional route.
Importantly, our peptide appears to colocalize with an-
nexin II, forming a complex indispensable for internalization in 
endosomes and transfer to the nucleus. Annexin II is a calcium-
dependent phospholipid-binding protein that is involved in 
early endosomal organization (Harder et al., 1997). Menaa et al. 
(1999) suggested that annexin II stimulates osteoclastogenesis 
and bone resorption by activating T cells through a putative re-
ceptor to secreted granulocyte M-CSF. In contrast, in our study, 
we found a pivotal role for this protein in the inhibitory effect   
of 
hbdPRELP on osteoclast formation through its indispensible 
ability to cause peptide internalization. This discrepancy does 
not subtract from the results as in the two studies, the cell types 
and the phases of osteoclastogenesis in which annexin II was 
involved were different and the physiological control of bone 
resorption is known to require a balance between stimulatory 
and inhibitory stimuli. Collectively, our results point to chon-
droitin sulfate cell surface proteoglycans and annexin II as  Figure 6.  Transcriptional regulation, signaling proteins, and apoptosis. 
(A)  Real-time  RT-PCR  analyses  of  mRNA  levels  in 
hbdPRELP-treated  puri-
fied prefusion osteoclasts relative to cultures treated with vehicle (set to 1; 
dashed line). Data, normalized versus the house-keeping gene Gapdh, 
are the mean ± SEM of three independent experiments (*, P < 0.05 vs. 
vehicle).  (B)  Purified  bone  marrow  macrophages,  treated  for  4  d  with   
M-CSF, were preincubated for 1 h with vehicle or 15 µM 
hbdPRELP and then 
with RANKL for 15 min. Cells were lysed, and Western blot analysis was 
performed for the indicated MAPKs. ERK, extracellular signal-regulated   
kinase; p, phospho. (C) Nuclei of prefusion osteoclasts treated with vehicle 
(top) or with 
hbdPRELP (bottom) were stained with DAPI to evaluate apopto-
sis. (D) Western blot analysis of prefusion osteoclasts for the detection of 
Bcl-2, Bax, and caspase 3 apoptosis-related proteins. Results are represen-
tative of three independent experiments.
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Figure 7.  Effect of 
hbdPRELP on osteoblasts. (A) Calvarial osteoblasts were fixed and incubated for 1 h with Alexa Fluor 488–
hbdPRELP and propidium 
iodide (PI). (B) Calvarial osteoblasts were incubated for 4 d with vehicle, 15 µM 
hbdPRELP, or 15 µM of control peptide. Cells were fixed, and ALP was 
detected (top) and quantified (bottom). (C) Details of von Kossa staining of mineralized nodules in calvarial osteoblasts treated with vehicle, 15 µM 
hbdPRELP, 
or 15 µM of control peptide (top) and relative quantification of mineralization in the whole cultures (bottom). (D) Western blot analysis of calvarial osteoblast 
lysates for the proteins indicated. (A–D) Data are representative of the mean ± SEM of three independent experiments. ERK, extracellular signal-regulated 
kinase; OPN, osteopontin; OSAD, osteoadherin; p, phospho. (E–G) Histomorphometric analysis of ovariectomized (OVX) mice treated with vehicle,   
10 mg/kg body weight of 
hbdPRELP or control peptide, and 1 mg/kg body weight of alendronate, as a reference drug, 5 d/wk for 5 wk. (E) Double   
in vivo calcein labeling. (E–G) Data are representative or the mean ± SD of five mice per group. ObS/BS, osteoblast surface/bone surface; MAR, mineral 
apposition rate.JCB • VOLUME 187 • NUMBER 5 • 2009   680
that treatment of prefusion osteoclasts with 
hbdPRELP does not 
affect RANKL-dependent MAPK phosphorylation, suggesting 
that the impairment of immediate cell signaling is not involved 
in its mechanism of action. It is also interesting that the suppres-
sion of NF-B to around 50% was sufficient to strongly sup-
press osteoclastic differentiation, likely reflecting the fact that 
massive NF-B activity is required for full induction of osteo-
clast formation. Furthermore, the PRELP peptide could exert 
additional roles at the cell surface by stimulating interactions 
with other cell surface molecules.
Notwithstanding the clear effect of 
hbdPRELP on osteo-
clast formation, we did not find any direct effect on in vitro 
bone resorption, as demonstrated in osteoclasts allowed to dif-
ferentiate normally and then transferred onto bone slices and 
treated with 
hbdPRELP. In this regard, it has to be pointed out 
that, although the pivotal role of RANKL-induced NF-B sig-
naling is well established for osteoclast formation, the effect of 
this signaling on the mechanism of bone resorption remains to 
be fully elucidated (Teitelbaum and Ross, 2003).
In conclusion, the heparin-binding domain of PRELP is a 
novel direct negative regulator of osteoclast generation, which 
is also effective in vivo. It inhibits NF-B signaling in late-stage 
crucial determinants bringing about Biotin
hbdPRELP endocytosis 
and trafficking.
A key element of our findings seems to be the ability of   
hbdPRELP to reach the nuclear compartment and form a complex 
with the p65 subunit of the transcription factor NF-B. In bone 
marrow macrophages, p65NF-B is translocated to the nucleus 
after RANK activation by RANKL. RANK appears in late   
osteoclast precursors (Teitelbaum and Ross, 2003), which is con-
sistent with our observation that 
hbdPRELP is active only in late 
stages of osteoclastogenesis. Indeed, in our experimental condi-
tions, Biotin
hbdPRELP and p65NF-B physically interact with   
a consequent reduction of NF-B activity. This transcription 
factor is central to the osteoclastogenic process, and deletion   
of NF-B subunits leads to blockage of osteoclast formation 
(Franzoso et al., 1997). Therefore, our observation favors the 
involvement of NF-B in the mechanism whereby 
hbdPRELP 
blocks osteoclastogenesis. Consistently, no sign of apoptosis 
was observed in prefusion osteoclasts treated with 
hbdPRELP. 
This observation is coherent with the results by Franzoso et al. 
(1997), showing that p52 and p50NF-B double gene inactiva-
tion in mice does not cause osteoclast death but rather halts the 
development of osteoclast precursors. It is interesting to note 
Figure  8.  Specificity  of  the 
hbdPRELP  effect.  
(A) Confocal microscopy of mouse bone marrow 
macrophages  (mBMMs)  vitally  incubated  for 
5, 10, and 20 min with 15 µM Alexa Fluor 
488–
hbdPRELP.  The  bottom  panels  represent 
the nuclear DAPI staining of the cells present 
in  the  corresponding  top  panels.  (B)  Con-
focal microscopy of mouse osteoclast-like cells 
(RAW264.7),  human  epithelial  kidney  cells 
(HEK293), human breast cancer cells (MDA-
MB231),  and  mouse  prefusion  osteoclasts 
(PreOCs)  vitally  incubated  for  20  min  with 
15 µM Biotin
hbdPRELP as described in A. The 
bottom middle and right panels represent the 
nuclear DAPI staining of the cells present in   
the corresponding top panels. Results are repre-
sentative of three independent experiments.681 PRELP and osteoclastogenesis • Rucci et al.
prefusion committed osteoclast precursors, with no effect on 
osteoblasts and other cell types tested. These observations could 
open new avenues for the understanding of the biology of osteo-
clasts and the involvement of matrix components in the regula-
tion of bone development and remodeling and could also have 
implications for the treatment of bone diseases.
Materials and methods
Peptides
Intact PRELP was extracted and purified from bovine nasal cartilage   
(Bengtsson et al., 2000). A synthetic human peptide (NH2-QPTRRPRPGTGPG-
RRPRPRPRPTPC-COOH) corresponding to the 24 N-terminal aa of PRELP and 
representing the active part of the heparin-binding domain (
hbdPRELP) was 
synthesized by Schafer-N with an additional cysteine residue in its C-terminal 
end. One preparation of the peptide was synthesized with a biotin at the   
C-terminal cysteine (Biotin
hbdPRELP), whereas another preparation was re-
acted  with  Alexa  Fluor  488  C5  maleimide  (Alexa  Fluor  488–
hbdPRELP;   
Invitrogen) according to the manufacturer’s instructions. The degree of de-
rivatization was estimated to be in excess of 90% and was verified by using 
MALDI-TOF (matrix-assisted laser desorption/ionization time of flight) mass 
spectrometry. In pilot experiments, we tested a different heparin-binding pep-
tide from chondroadherin of 14 aa (NH2-CKFPTKRSKKAGRH-COOH), cor-
responding to the C-terminal part of chondroadherin. This peptide turned out 
to be ineffective on osteoclast development and was used as a control.
Animals
Procedures involving animals and their care were conducted in conformity 
with  national  and  international  laws  and  policies  (European  Economic 
Community Council Directive 86/609, OJ L 358, 1, December 12, 1987; 
Italian Legislative Decree 116/92, Gazzetta Ufficiale della Repubblica 
Italiana no. 40, February 18, 1992; National Institutes of Health guide for 
the Care and Use of Laboratory Animals, National Institutes of Health Pub-
lication no. 85-23, 1985) and were approved by the Institutional Review 
Board of the University of L’Aquila.
In vivo study
8-wk-old female C57Bl6/J mice were ovariectomized and, after 3 d, were 
treated with vehicle (PBS), control peptide (10 mg/kg body weight), 
hbdPRELP 
(10 mg/kg body weight), or alendronate (1 mg/kg body weight) by i.p. 
injection 5 d/wk for 5 wk (number of animals/group = 5). At the end of 
the experiment, urine samples were collected for detection of CTX assay by 
the Ratlaps ELISA kit (IDS Nordic Bioscience) according to the manufactur-
er’s instructions. Animals were then sacrificed, and the hindlimb long bones 
were removed and fixed in 4% paraformaldehyde.
Histomorphometric analysis
Tibiae,  embedded  in  glycol-methacrylate  (Technovit  9100  New;  Heraeus   
Kulzer GmbH), were sectioned longitudinally through the frontal plate, and 
sections (2 µm thick) were subjected to TRAcP staining. Osteoclast number/
bone surface (number/square millimeters), osteoclast surface/bone surface 
(percentage), osteoblast surface/bone surface (percentage), and structural pa-
rameters, including bone volume/total volume (percentage), trabecular num-
ber (number/millimeter), trabecular thickness (micrometers), and trabecular 
separation (micrometers), were measured in a metaphyseal region extending 
at least 100 µm away from the distal end of the growth plate and excluding 
the endocortical surfaces (secondary spongiosa; Parfitt et al., 1987; Marzia 
et al., 2000). Dynamic assessment of the mineral apposition rate was calcu-
lated after double injection of calcein 10 and 3 d before animal sacrifice. Histo-
morphometric  measurements  were  performed  with  an  interactive  image 
analysis system (IAS 2000; Delta Sistemi) consisting of a color video–equipped 
computer linked to the microscope by a video camera.
Osteoclast cultures
Bone marrow was flushed from the long bones of 7-d-old CD1 mice. Cells 
were recovered and cultured in DME plus 10% FBS up to 6 d in the presence 
of 10
8 M 1,25(OH)2VitaminD3. To obtain purified bone marrow macro-
phages, bone marrow cells from 7-d-old mice or rats were diluted 1:1 in 
Hanks’ balanced salt solution, layered over Histopaque 1077, and centri-
fuged at 400 g for 30 min. Cells recovered were resuspended in DME con-
taining 10% FBS and plated. After 3 h, cultures were extensively washed to 
remove nonadherent cells, and then DME supplemented with 10% FBS,   
50 ng/ml M-CSF, and 120 ng/ml RANKL was added to adherent cells to   
induce osteoclastogenesis. Human osteoclasts were differentiated from the 
peripheral blood mononuclear cells. In brief, diluted blood (1:1 in Hanks’ 
solution) was layered over Ficoll/Histopaque 1077 solution and centrifuged 
at 400 g for 30 min. Buffy-coat cells thus isolated were washed twice with 
Hanks’ solution, resuspended in DME containing 10% FBS, and plated. After 
3 h, cells were rinsed to remove nonadherent cells and cultured in the same 
medium in the presence of 50 ng/ml M-CSF and 30 ng/ml RANKL. Unless 
otherwise stated, treatment of osteoclast cultures with 
hbdPRELP or control 
peptide started the third day of culture, affecting only adherent cells referred 
to as prefusion osteoclasts, which are defined as TRAcP-positive mononuclear 
cells. The peptide was replaced at each change of medium.
Enzymatic treatments
To assess the involvement of cell surface proteoglycans carrying heparin 
sulfate or chondroitin sulfate chains in the inhibitory effect of PRELP, osteo-
clastogenesis was performed in the presence of 2 U/ml heparinase III or 
0.45 U/ml chondroitinase ABC, respectively. The enzymes were replaced 
at each change of medium. At the end of the experiment, enzymatic activ-
ity was terminated by extensive washing of the cultures, which were then 
fixed in 4% paraformaldehyde.
TRAcP activity
Cells were fixed in 4% paraformaldehyde, and then TRAcP activity was 
evaluated histochemically using the Sigma-Aldrich kit #386 according to 
the manufacturer’s instruction.
Bone resorption
Osteoclasts were differentiated as described in the Osteoclast cultures sec-
tion onto bone slices or were differentiated in plastic dishes, detached by 
trypsin procedure, and cultured onto bone slices for 48 h. Slices were then 
fixed in 4% paraformaldehyde, ultrasonicated in 1% sodium hypochlorite 
to remove the cells, and stained with 1% toluidine blue. Pit index was com-
puted according to Caselli et al. (1997). In brief, the resorption pits were 
divided in three visual categories according to their diameter: small, <10 µm; 
medium, 10–30 µm; and large, >30 µm. The numbers of pits per each cat-
egory were scored by multiplying by a different factor according to their 
dimensions: for small pits, 0.3; for medium pits, 1; and for large pits, 3. 
The sum of the three scores gave the pit index.
Osteoblast cultures
Calvariae were removed from 7-d-old CD1 mice and digested three times 
with 1 mg/ml Clostridium histolyticum type IV collagenase and 0.25% 
trypsin for 20 min at 37°C. Cells from the second and third digestions were 
grown in DME plus 10% FBS and checked for the expression of the osteo-
blast markers ALP, Runx2 (Runt-related transcription factor-2), PTHrP (para-
thyroid hormone/parathyroid hormone–related peptide receptor), type I 
collagen, and osteocalcin (Marzia et al., 2000).
ALP activity
Osteoblasts were fixed in 4% paraformaldehyde, and then ALP activity 
was evaluated histochemically using the Sigma-Aldrich kit #85 according 
to the manufacturer’s instruction.
Mineralization assay
Osteoblast standard medium was supplemented with 10 mM -glycero-
phosphate and 50 µg/ml ascorbate. Osteoblasts were cultured for 3 wk 
before characterization of mineralization by von Kossa staining.
Adhesion assay
Osteoclast-enriched bone marrow cultures were trypsinized and treated 
in suspension for 30 min with vehicle alone or with 15 µM peptide in 
FBS-free DME. Cells were then plated in wells coated with 20% FBS. At 
the end of the incubation, attached cells were fixed and subjected to 
TRAcP histochemical staining. Multinucleated TRAcP-positive osteoclasts 
were then enumerated.
Real-time RT-PCR
Total RNA was extracted using the TRIZOL, and then 1 µg was reverse 
transcribed, and the equivalent of 0.1 µg was used for the PCR reactions 
using the Brilliant SYBR green QPCR master mix (Agilent Technologies). 
Primer sequences and real-time conditions are listed in Table S2.
Immunoprecipitation and Western blotting
Cells were lysed in radioimmunoprecipitation assay (RIPA) buffer, and pro-
tein content was measured by the Bradford method. For immunoprecipita-
tion, 5 µg of specific antibodies or preimmune serum was incubated for   JCB • VOLUME 187 • NUMBER 5 • 2009   682
Online supplemental material
Fig. S1 shows the effect of 
hbdPRELP on bone resorption and evaluation 
of its internalization. Fig. S2 shows the effect of 
hbdPRELP on mice, rat, 
and human osteoclast formation. Fig. S3 shows the effect of 
hbdPRELP on 
MDA-MB231 cell proliferation, migration, and invasion. Fig. S4 contains 
a schematic representation of the intact PRELP protein. Table S1 shows the 
effect of 
hbdPRELP on the transcriptional expression of osteoblast genes. 
Table  S2  lists  the  primer  sequences  and  real-time  conditions  used  in 
this study. Online supplemental material is available at http://www.jcb 
.org/cgi/content/full/jcb.200906014/DC1.
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2 h at 4°C with protein G–conjugated agarose beads. After five washes in 
RIPA buffer, 1 mg of protein of each sample was added and incubated 
overnight at 4°C. Samples were then washed with RIPA buffer, resuspended 
in 2× reducing Laemmli sample buffer, and boiled before SDS-PAGE.
For Western blots, proteins resolved on a 10% SDS-PAGE were 
trans-blotted to nitrocellulose membranes and probed with the primary 
antibody for 1 h at room temperature, washed, and incubated with the 
appropriate HRP-conjugated secondary antibody for 1 h at room temper-
ature. In Fig. 4 B, blots were first incubated with Biotin
hbdPRELP and then 
washed and incubated with streptavidin/HRP. Protein bands were re-
vealed by ECL.
p65NF-B binding activity
p65NF-B binding to DNA was evaluated using the ELISA TransAM NF-B 
p65 kit #40096 (Active Motif) according to the manufacturer’s instructions. 
In brief, the kit consists of a 96-well plate with an immobilized oligonucleo-
tide  containing  a  p65NF-B  consensus  binding  site.  The  activated 
p65NF-B contained in cell extracts specifically bound to this oligonucleo-
tide, and then the complex was detected by an antibody directed against 
the p65NF-B subunit. The addition of an HRP-conjugated secondary anti-
body provided sensitive colorimetric readout.
Luciferase assay
RAW264.7 cells were transfected with 1.35 µg of pNF-B–Luc vector 
(Takara Bio Inc.), 1.35 µg of pMT2T-p65 vector, and 0.3 µg of pRL-TK vec-
tor using Lipofectamine 2000 (Invitrogen). After 36 h, cells were harvested, 
and lysates were incubated with the Luciferase Assay Substrate by using 
the Dual-Luciferase Reporter Assay system (Promega) according to the 
manufacturer’s instruction. Firefly luciferase activity was normalized to 
Renilla luciferase activity.
Proliferation, migration, and invasion assays
Proliferation of MDA-MB231 cells was evaluated using the CellTiter 96 
Aqueous One Solution Cell Proliferation Assay (MTS) from Promega. Mi-
gration assay was performed by the modified Boyden chamber method 
(Albini et al., 1987). Polycarbonate filters were coated with 45 µg/cm
2 
gelatin in the upper compartment of the trans-well chambers, and MDA-
MB231 cells were added and allowed to migrate for 12 h in the presence of 
NIH3T3 cell–conditioned media. Filters were then stained with hematoxylin/
eosin. Invasion assay was performed in a similar manner except that the 
filters were coated with 35 µg/cm
2 of reconstituted matrigel and processed 
after 24 h.
Fluorescence and confocal microscopy
Cells were fixed with 4% paraformaldehyde and incubated for 1 h at room 
temperature with Alexa Fluor 488–conjugated 
hbdPRELP (Alexa Fluor 488–
hbdPRELP) or primary antibodies followed by FITC- or TRITC-conjugated sec-
ondary  antibody.  Cells  were  also  incubated  vitally  with  Biotin
hbdPRELP, 
which was revealed by fluorescent biotin 594-streptavidin. To detect   
nuclei, cells were stained with DAPI (blue fluorescence) or with propidium 
iodide (red fluorescence). Cells were then observed at room temperature 
by conventional epifluorescence using a microscope (Axioplan; Carl Zeiss, 
Inc.) or by confocal microscopy using a confocal microscope (FluoView 
IX81 FVBF; Olympus). For fluorescence microscopy, we used 2.5× NA 
0.075, 10× NA 0.30, 20× NA 0.5, and 40× NA 0.75 Plan-Neofluar ob-
jective lenses. Images were captured with a camera (AxioCam MRC5; 
Carl Zeiss, Inc.) using the AxioVs 40 version 4.7.1.0 software (Carl Zeiss, 
Inc.). For confocal microscopy, we used 10× NA 0.30 and 40× NA 0.85 
UPlan-Apochromat or 60× NA 1.4 oil Plan-Apochromat objective lenses. 
Images were captured using FluoView 500 software (Olympus).
Digital images
Light, fluorescence, and confocal microscopy pictures were captured as 
JPEG files as specified in the previous section. Western blots images were 
captured by the Molecular Analyst software for the model 670 scanning 
densitometer (Bio-Rad Laboratories) as JPEG files. The areas of interest 
were selected and reproduced for documentation by Photoshop version 6 
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